EMA Withdrawn: Duloxetine Boehringer Ingelheim (duloxetine) — Boehringer Ingelheim International GmbH

View source ↗

Summary

Duloxetine (Boehringer Ingelheim) product withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathies

Drugs mentioned

• Duloxetine (DULOXETINE)

Snippet

Status: Withdrawn. Therapeutic area: Diabetic Neuropathies. MAH: Boehringer Ingelheim International GmbH. Decision date: 07/12/2009